文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胶质母细胞瘤的新型手术、放疗和系统治疗及临床试验述评。

Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma.

机构信息

Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.

Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Int J Mol Sci. 2024 Sep 30;25(19):10570. doi: 10.3390/ijms251910570.


DOI:10.3390/ijms251910570
PMID:39408897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11477105/
Abstract

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Despite an established standard of care including surgical resection, radiation therapy, and chemotherapy, GBM unfortunately is associated with a dismal prognosis. Therefore, researchers are extensively evaluating avenues to expand GBM therapy and improve outcomes in patients with GBM. In this review, we provide a broad overview of novel GBM therapies that have recently completed or are actively undergoing study in clinical trials. These therapies expand across medical, surgical, and radiation clinical trials. We additionally review methods for improving clinical trial design in GBM.

摘要

胶质母细胞瘤(GBM)是成人中最常见的恶性原发性脑肿瘤。尽管已经确立了包括手术切除、放射治疗和化学治疗在内的标准治疗方法,但不幸的是,GBM 的预后仍然很差。因此,研究人员正在广泛评估扩大 GBM 治疗并改善 GBM 患者预后的途径。在这篇综述中,我们提供了最近在临床试验中完成或正在积极进行研究的新型 GBM 治疗方法的广泛概述。这些治疗方法涵盖了医学、外科和放射临床试验。我们还回顾了改善 GBM 临床试验设计的方法。

相似文献

[1]
Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma.

Int J Mol Sci. 2024-9-30

[2]
Novel Clinical Trials and Approaches in the Management of Glioblastoma.

Curr Oncol Rep. 2024-5

[3]
A review of glioblastoma immunotherapy.

J Neurooncol. 2021-1

[4]
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.

Anticancer Res. 2017-1

[5]
Management of glioblastoma in elderly patients.

J Neurol Sci. 2017-8-1

[6]
Combination immunotherapy strategies for glioblastoma.

J Neurooncol. 2021-2

[7]
RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Life Sci. 2017-11-1

[8]
Recent advances in therapy for glioblastoma.

Arch Neurol. 2010-3

[9]
Updates for newly diagnosed and recurrent glioblastoma: a review of recent clinical trials.

Curr Opin Neurol. 2024-12-1

[10]
Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.

Chin Clin Oncol. 2017-8

引用本文的文献

[1]
Progenitor cells, microglia, and non-coding RNAs: Orchestrators of glioblastoma pathogenesis and therapeutic resistance.

Noncoding RNA Res. 2025-8-5

[2]
Tumor-specific PET tracer imaging and contrast-enhanced Mri based tumor volume differences inspection of glioblastoma patients.

Sci Rep. 2025-8-16

[3]
CRISPR-Cas9 screening identifies a gene signature predictive of prognosis in glioblastoma.

Sci Rep. 2025-7-1

[4]
Functional Biomaterials: Scaffolds for Innovative Treatments.

J Funct Biomater. 2025-4-27

[5]
Coordinated regulation of IGF1R by HIF1α and HIF2α enhances chemoresistance in glioblastoma.

Front Pharmacol. 2025-4-11

[6]
Potential of Curcumin and Its Analogs in Glioblastoma Therapy.

Antioxidants (Basel). 2025-3-18

[7]
Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches.

Med Oncol. 2025-3-10

[8]
Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?

Diagnostics (Basel). 2025-2-11

[9]
Glioblastoma Cell Migration, Invasion and Vasculogenic Mimicry Downmodulated by Novel uPAcyclin Derivatives.

Cells. 2025-2-12

本文引用的文献

[1]
Peptostreptococcus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice.

Nat Microbiol. 2024-6

[2]
CAR T-Cell Therapy for Glioblastoma.

N Engl J Med. 2024-4-11

[3]
Antiangiogenic exclusion rules in glioma trials: Historical perspectives and guidance for future trial design.

Neurooncol Adv. 2024-3-15

[4]
Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas.

Curr Oncol Rep. 2024-4

[5]
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.

Nat Med. 2024-5

[6]
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.

N Engl J Med. 2024-4-11

[7]
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.

BMC Cancer. 2024-1-15

[8]
Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial.

Nat Commun. 2024-1-12

[9]
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults.

J Clin Oncol. 2023-11-20

[10]
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.

J Clin Oncol. 2023-12-20

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索